MARKET

CRBU

CRBU

Caribou Biosciences, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.30
+1.16
+14.25%
Pre Market: 9.50 +0.2 +2.15% 08:01 08/11 EDT
OPEN
8.11
PREV CLOSE
8.14
HIGH
9.37
LOW
7.85
VOLUME
2
TURNOVER
--
52 WEEK HIGH
32.65
52 WEEK LOW
4.890
MARKET CAP
564.56M
P/E (TTM)
-3.7615
1D
5D
1M
3M
1Y
5Y
--RBC Cuts Price Target on Caribou Biosciences to $19 From $22, Maintains Outperform Rating, Speculative Risk Qualifier
--RBC Cuts Price Target on Caribou Biosciences to $19 From $22, Maintains Outperform Rating, Speculative Risk Qualifier
MT Newswires · 1d ago
Recap: Caribou Biosciences Q2 Earnings
  Caribou Biosciences (NASDAQ:CRBU) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Benzinga · 1d ago
BRIEF-Caribou Biosciences Files For Mixed Shelf Of Up To $400 Mln
BRIEF-Caribou Biosciences Files For Mixed Shelf Of Up To $400 Mln
Reuters · 1d ago
Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates
Caribou Biosciences, Inc. (CRBU) delivered earnings and revenue surprises of -24.32% and 48.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 1d ago
Caribou Bioscience GAAP EPS of -$0.44 misses by $0.08, revenue of $4.19M beats by $1.33M
Caribou Bioscience press release (<span class="tic...
Seekingalpha · 1d ago
Caribou Biosciences Q2 EPS $(0.44) Up From $(1.39) YoY, Sales $4.19M Up From $1.48M YoY
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.44) per share. This is a 68.35 percent increase over losses of $(1.39) per share from the same period last year. The company reported $4.19 million in
Benzinga · 1d ago
BRIEF-Caribou Biosciences Reports Second Quarter 2022 Financial Results
BRIEF-Caribou Biosciences Reports Second Quarter 2022 Financial Results
Reuters · 1d ago
-- Earnings Flash (CRBU) CARIBOU BIOSCIENCES Posts Q2 Loss $-0.44
-- Earnings Flash (CRBU) CARIBOU BIOSCIENCES Posts Q2 Loss $-0.44
MT Newswires · 1d ago
More
No Data
Learn about the latest financial forecast of CRBU. Analyze the recent business situations of Caribou Biosciences, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

57.14%Strong Buy
42.86%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CRBU stock price target is 29.00 with a high estimate of 39.00 and a low estimate of 19.00.
High39.00
Average29.00
Low19.00
Current 9.30
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Institutional Holdings
Institutions: 104
Institutional Holdings: 34.25M
% Owned: 56.42%
Shares Outstanding: 60.71M
TypeInstitutionsShares
Increased
43
6.96M
New
22
522.37K
Decreased
18
3.16M
Sold Out
11
1.28M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.06%
Pharmaceuticals & Medical Research
+0.92%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Rachel Haurwitz
Chief Financial Officer/Primary Contact
Jason O'byrne
Senior Vice President
Cherry Thomas
Chief Scientific Officer
Steven Kanner
Other
Ruhi Khan
Other
Syed Rizvi
Secretary
Barbara McClung
Director
David Johnson
Director
Dara Richardson - Heron
Director
Nancy Whiting
Director
Ran Zheng
Independent Director
Scott Braunstein
Independent Director
Andrew Guggenhime
Independent Director
Natalie Sacks
No Data
No Data
About CRBU
Caribou Biosciences, Inc. is a clinical-stage genome-editing biopharmaceutical company. The Company is developing transformative clustered regularly interspaced short palindromic repeats (CRISPR) therapies for patients with devastating diseases. The Company’s CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), enables superior genome-editing precision to develop cell therapies that are specifically engineered for enhanced persistence. It is advancing a pipeline of allogeneic, or off-the-shelf, chimeric antigen receptor (CAR)-T (CAR-T) and CAR-natural killer (CAR-NK) cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Its lead product candidate, CB-010, is a clinical-stage allogeneic anti-CD19 CAR-T cell therapy with programmed cell death protein 1 (PD-1) removed from the CAR-T cell surface by a genome-edited knockout of the PDCDI gene. The Company’s product candidate also includes CB-011, CB-012 and CB-012.

Webull offers kinds of Caribou Biosciences Inc stock information, including NASDAQ:CRBU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRBU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRBU stock methods without spending real money on the virtual paper trading platform.